EBITDA What is it, and why does it matter? The Oncology Valuation Series November 21, 2018 Wes Chapman President & CEO of Verdi Oncology, Inc. My job puts me in front of physician owners of medical oncology practices at least 4-5 times per month, and invariably [...]
Read more
240% Growth in Oncology Drug Approvals in 2017 Good News for Cancer Patients Wes Chapman January 2, 2018 Introduction Advances in medical oncology depend on successful drug development – and that means successful clinical trials, leading to approval by the FDA for compounds that materially [...]
Read more
MIPS/MACRA 2018 Strategic Considerations for Medical Oncology Practices Implications of a Zero Sum Game Wes Chapman December 2017 A Doomsday Solution to a Zero Sum Game Strategic Situational Analysis MACRA/MIPS (MIPS) will become the operational standard in 2018 by which CMS evaluates: 1) The quality of care [...]
Read more
340B Medical Oncology Practices and Hospitals - Time to Bail Out? November 20, 2017 Wes Chapman Time to Bail Out of 340B? On November 1st, CMS announced sweeping changes in the reimbursement of 340B eligible drugs, “Today, the Centers for Medicare & Medicaid Services [...]
Read more
Hey, President Trump, To fix the Healthcare mess, listen to the dog that didn’t bark! Dr. Grant Bagley & Wes Chapman July 4, 2017 Preface: This is the first in an occasional series of articles looking at selected healthcare policy issues best addressed by [...]
Read more